Limits...
Screening Ultrasound in Women with Negative Mammography: Outcome Analysis.

Hwang JY, Han BK, Ko EY, Shin JH, Hahn SY, Nam MY - Yonsei Med. J. (2015)

Bottom Line: We analyzed the distribution of Breast Imaging Reporting and Data System (BI-RADS) category and the performance outcome through follow up.The recall rate (=BI-RADS category 3, 4, 5) was 5.8%.The sensitivity, specificity, and positive predictive value (PPV1, PPV2) were 88.9%, 94.6%, 8.0%, and 28.0%, respectively.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

ABSTRACT

Purpose: To show the results of an audit of screening breast ultrasound (US) in women with negative mammography in a single institution and to analyze US-detected cancers within a year and interval cancers.

Materials and methods: During the year of 2006, 1974 women with negative mammography were screened with US in our screening center, and 1727 among them had pathologic results or any follow up breast examinations more than a year. We analyzed the distribution of Breast Imaging Reporting and Data System (BI-RADS) category and the performance outcome through follow up.

Results: Among 1727 women (age, 30-76 years, median 49.5 years), 1349 women (78.1%) showed dense breasts on mammography, 762 (44.1%) had previous breast US, and 25 women (1.4%) had a personal history of breast cancers. Test negatives were 94.2% (1.627/1727) [BI-RADS category 1 in 885 (51.2%), 2 in 742 (43.0%)]. The recall rate (=BI-RADS category 3, 4, 5) was 5.8%. Eight cancers were additionally detected with US (yield, 4.6 per 1000). The sensitivity, specificity, and positive predictive value (PPV1, PPV2) were 88.9%, 94.6%, 8.0%, and 28.0%, respectively. Eight of nine true positive cancers were stage I or in-situ cancers. One interval cancer was stage I cancer from BI-RADS category 2.

Conclusion: Screening US detected 4.6 additional cancers among 1000. The recall rate was 5.8%, which is in lower bound of acceptable range of mammography (5-12%), according to American College of Radiology standard.

No MeSH data available.


Related in: MedlinePlus

A US-detected cancer in a 49-year-old woman that was initially assessed as BI-RADS category 4A (case 2 in Table 3). US shows an illdefined oval hypoechoic mass in right breast and it was assessed as category 4A. The pathologic diagnosis was invasive ductal cancer with ductal carcinoma in situ. US, ultrasound; BI-RADS, Breast Imaging Reporting and Data System.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4541666&req=5

Figure 4: A US-detected cancer in a 49-year-old woman that was initially assessed as BI-RADS category 4A (case 2 in Table 3). US shows an illdefined oval hypoechoic mass in right breast and it was assessed as category 4A. The pathologic diagnosis was invasive ductal cancer with ductal carcinoma in situ. US, ultrasound; BI-RADS, Breast Imaging Reporting and Data System.

Mentions: Eight US-detected carcinomas were invasive ductal cancers (IDCs); 7 were ductal carcinoma in situ, and intraductal papilloma in 1 (Fig. 4, case 2 in Table 3). There were 6 stage I-cancer (T1N0 or T1N1mi) and 1 stage II-cancer (T2N0) under the AJCC 7th edition classification.24 One US-miscategorized interval cancer was a stage I IDCs without lymph node metastasis (Table 3).


Screening Ultrasound in Women with Negative Mammography: Outcome Analysis.

Hwang JY, Han BK, Ko EY, Shin JH, Hahn SY, Nam MY - Yonsei Med. J. (2015)

A US-detected cancer in a 49-year-old woman that was initially assessed as BI-RADS category 4A (case 2 in Table 3). US shows an illdefined oval hypoechoic mass in right breast and it was assessed as category 4A. The pathologic diagnosis was invasive ductal cancer with ductal carcinoma in situ. US, ultrasound; BI-RADS, Breast Imaging Reporting and Data System.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4541666&req=5

Figure 4: A US-detected cancer in a 49-year-old woman that was initially assessed as BI-RADS category 4A (case 2 in Table 3). US shows an illdefined oval hypoechoic mass in right breast and it was assessed as category 4A. The pathologic diagnosis was invasive ductal cancer with ductal carcinoma in situ. US, ultrasound; BI-RADS, Breast Imaging Reporting and Data System.
Mentions: Eight US-detected carcinomas were invasive ductal cancers (IDCs); 7 were ductal carcinoma in situ, and intraductal papilloma in 1 (Fig. 4, case 2 in Table 3). There were 6 stage I-cancer (T1N0 or T1N1mi) and 1 stage II-cancer (T2N0) under the AJCC 7th edition classification.24 One US-miscategorized interval cancer was a stage I IDCs without lymph node metastasis (Table 3).

Bottom Line: We analyzed the distribution of Breast Imaging Reporting and Data System (BI-RADS) category and the performance outcome through follow up.The recall rate (=BI-RADS category 3, 4, 5) was 5.8%.The sensitivity, specificity, and positive predictive value (PPV1, PPV2) were 88.9%, 94.6%, 8.0%, and 28.0%, respectively.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

ABSTRACT

Purpose: To show the results of an audit of screening breast ultrasound (US) in women with negative mammography in a single institution and to analyze US-detected cancers within a year and interval cancers.

Materials and methods: During the year of 2006, 1974 women with negative mammography were screened with US in our screening center, and 1727 among them had pathologic results or any follow up breast examinations more than a year. We analyzed the distribution of Breast Imaging Reporting and Data System (BI-RADS) category and the performance outcome through follow up.

Results: Among 1727 women (age, 30-76 years, median 49.5 years), 1349 women (78.1%) showed dense breasts on mammography, 762 (44.1%) had previous breast US, and 25 women (1.4%) had a personal history of breast cancers. Test negatives were 94.2% (1.627/1727) [BI-RADS category 1 in 885 (51.2%), 2 in 742 (43.0%)]. The recall rate (=BI-RADS category 3, 4, 5) was 5.8%. Eight cancers were additionally detected with US (yield, 4.6 per 1000). The sensitivity, specificity, and positive predictive value (PPV1, PPV2) were 88.9%, 94.6%, 8.0%, and 28.0%, respectively. Eight of nine true positive cancers were stage I or in-situ cancers. One interval cancer was stage I cancer from BI-RADS category 2.

Conclusion: Screening US detected 4.6 additional cancers among 1000. The recall rate was 5.8%, which is in lower bound of acceptable range of mammography (5-12%), according to American College of Radiology standard.

No MeSH data available.


Related in: MedlinePlus